Jing Sun

Associate Research Professor

Johns Hopkins University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Background Circulating cell-free mitochondrial DNA (ccf-mtDNA) fragments are released into the bloodstream following cell death and are associated with comorbidities seen in people with HIV-1 (PWH). However, ccf-mtDNA dynamics in acute and chronic HIV infection remain unclear. Methods We quantified short and long ccf-mtDNA fragments in serum from 2 cohorts of PWH and people without HIV (PWoH), collected at 1, 3, and 5 years in the first cohort (N = 890) and 1 and 5 years in the second (N = 427). Mixed-effect linear regression models were used to analyze longitudinal associations of ccf-mtDNA levels with HIV status and markers (CD4-cell count, viral load). In parallel, we examined ccf-mtDNA levels in nonhuman primates (NHPs) before and after simian immunodeficiency virus (SIV) infection and following 3 and 6 months of ART. Results In both human cohorts, PWH had significantly lower levels of short and long ccf-mtDNA fragments compared with PWoH. Individuals with lower CD4 T-cell counts exhibited further reductions in ccf-mtDNA levels. In NHPs, short ccf-mtDNA levels increased after infection, peaking before ART initiation (P = .001), and subsequently declined, reaching levels below baseline after 6 months on ART. Long ccf-mtDNA fragments remained stable during the early post-ART phase but declined significantly by 6 months (P = .02). Conclusions Chronic HIV infection and treated SIV infection are associated with reduced ccf-mtDNA levels, particularly in advanced disease stages. Further research is needed to clarify their role in immune activation, chronic inflammation, and aging-related comorbidities in PWH and their applicability as clinically relevant biomarkers of these processes.

Year:

2026

Background and Aims Persons who inject drugs (PWID) experience a high burden of early‐onset frailty, primarily due to multifactorial causes such as infections (human immunodeficiency virus [HIV], hepatitis C virus [HCV]), substance use, and polypharmacy. Methadone, although an effective treatment for opioid use disorder, has demonstrated toxicity across several body systems that may impact or accelerate the aging process. Therefore, the purpose of this analysis was to determine the association of methadone use with frailty and physical function among PWID. Design This study performed a retrospective analysis from the AIDS Linked to IntraVenous Experience (ALIVE) longitudinal cohort between 2005 and 2020, using multivariable mixed effect logistic regression, adjusting for demographics, body mass index, substance use, HIV, and comorbidities. Setting Baltimore, Maryland, United States. Participants Adult participants (≥18 years) were recruited into the ALIVE cohort if they reported a history of or current injection drug use. Our study included 2153 participants with 13 909 person‐years of follow‐up. Measurements Methadone usage, whether prescribed or non‐medical, was self‐reported by participants during study follow‐up. The primary outcome measurement was frailty as defined by the Fried frailty phenotype. Physical function was measured using grip strength and 4‐m gait speed. Findings At baseline, 883 were currently using methadone. Median age was 48 (interquartile range: 42, 53) years; 81% were Black, 34% female, 80% had incomes <$5000, and 31% were living with HIV. Methadone use was associated with 25% higher odds of frailty (95% confidence interval [CI]: 1.09, 1.43). This difference suggested that the odds of frailty among individuals using methadone at age 50 were comparable to those not using methadone at age 54. Methadone use was associated with lower average grip strength [−0.71 kg (95% CI: −0.94, −0.48)], but not slower gait speed. Conclusions Among persons who inject drugs, those using methadone appear to be more likely to experience frailty at an earlier age compared with those not using methadone. Early screening for frailty and other geriatric conditions may be warranted among individuals with active methadone use in this population.

Year:

2025

Supplementary Table S1 shows Clinical information of US/EU patients analyzed. Supplementary Table S2 is a summary of whole genome cfDNA analyses. Supplementary Table S3 shows clinical information of Hong Kong patients analyzed. Supplementary Table S4 shows the lowest scoring transcription factors in US/EU cohort samples. Supplementary Table S5 lists the plasma volume and cfDNA amounts used in genomic libraries.

Year:

2025

Supplementary Figure S1 shows contributions of individual genomic regions to the final trained DELFI surveillance model. Supplementary Figure S2 shows DELFI scores in individuals without cancer by age and sex. Supplementary Figure S3 shows DELFI scores in high-risk individuals without cancer across racial or ethnic groups. Supplementary Figure S4 shows DELFI scores in cirrhotic patients in relation to severity. Supplementary Figure S5 shows DELFI scores in individuals in relation to BMI. Supplementary Figure S6 Shows Performance of alternative DELFI models. Supplementary Figure S7 shows Correlation between rank ordered DELFI. Supplementary Figure S8 shows DELFI scores in patients with HCC were related to tumor characteristics. Supplementary Figure S9 shows DELFI scores in by etiology of underlying liver disease. Supplementary Figure S10 shows the DELFI score in patients with HCC is correlated to AFP levels. Supplementary Figure S11 shows the correlation of fragmentation profiles. Supplementary Figure S12 shows Genome wide fragmentation profiles in the Hong Kong validation cohort Supplementary Figure S13 shows chromosomal copy number in Hong Kong cohort. Supplementary Figure S14 shows the implementation of DELFI in liver cancer screening.

Year:

2025

Objectives Long COVID is a debilitating condition that impacts millions of Americans, but patients and clinicians have little information on how to prevent this disorder. Vaccination is a vital tool in preventing acute COVID-19 and may confer additional protection against Long COVID. There is limited evidence regarding the optimal timing of COVID-19 vaccination (i.e., vaccination schedule) to minimize the risk of Long COVID. Methods We applied Longitudinal Targeted Maximum Likelihood Estimation to electronic health record (EHR) data from a retrospective cohort of patients vaccinated against COVID-19 between December 2021 and September 2022. We evaluated the association between binary COVID-19 vaccination status (two or more doses vs. zero doses) and 12-month Long COVID risk among patients diagnosed with acute COVID-19 between December 2021 and September 2022. In addition, we compared the 12-month cumulative risk of Long COVID (ICD-10 code U09.9) among patients diagnosed with acute COVID-19 one to three months after vaccination, three to five months after vaccination, or five to seven months after vaccination while adjusting for relevant high-dimensional baseline and time-dependent covariates. Results We analyzed EHR data from a retrospective cohort of 1,558,018 patients. In our binary cohort ( n = 519,980), we found that vaccinated patients had a lower risk of Long COVID than unvaccinated patients (adjusted marginal risk ratio 0.84 (0.81, 0.88)). In our longitudinal cohort ( n = 1,085,291), we did not find a significant difference in Long COVID risk comparing patients who were diagnosed with acute COVID-19 one to three months after vaccination versus patients who were diagnosed with COVID-19 three to five months (adjusted marginal risk ratio 0.93 (95% CI 0.62, 1.41) or 5 to 7 months (adjusted marginal risk ratio 1.06 (95% CI 0.72, 1.56)) after vaccination. Conclusions We found that COVID-19 vaccination before SARS-CoV-2 infection was protective against Long COVID, and we did not find that this protection significantly waned within 7 months after vaccination. These findings suggest that COVID-19 vaccination protects against Long COVID.

Year:

2025

BACKGROUND Electronic health records (EHRs) provide valuable insights to address clinical and epidemiological research concerning HIV, including the disproportionate impact of the COVID-19 pandemic on people living with HIV. To identify this population, most studies using EHR or claims databases start with diagnostic codes, which can result in misclassification without further refinement using drug or laboratory data. Furthermore, given that antiretrovirals now have indications for both HIV and COVID-19 (ie, ritonavir in nirmatrelvir/ritonavir), new phenotyping methods are needed to better capture people living with HIV. Therefore, we created a generalizable and innovative method to robustly identify people living with HIV, preexposure prophylaxis (PrEP) users, postexposure prophylaxis (PEP) users, and people not living with HIV using granular clinical data after the emergence of COVID-19. OBJECTIVE The primary aim of this study was to use computational phenotyping in EHR data to identify people living with HIV (cohort 1), PrEP users (cohort 2), PEP users (cohort 3), or “none of the above” (people not living with HIV; cohort 4) and describe COVID-19–related characteristics among these cohorts. METHODS We used diagnostic and laboratory measurements and drug concepts in the National Clinical Cohort Collaborative to create a computational phenotype for the 4 cohorts with confidence levels. For robustness, we conducted a randomly sampled, blinded clinician annotation to assess precision. We calculated the distribution of demographics, comorbidities, and COVID-19 variables among the 4 cohorts. RESULTS We identified 132,664 people living with HIV with a high level of confidence, 36,088 PrEP users, 4120 PEP users, and 20,639,675 people not living with HIV. Most people living with HIV were identified by a combination of medical conditions, laboratory measurements, and drug exposures (74,809/132,664, 56.4%), followed by laboratory measurements and drug exposures (15,241/132,664, 11.5%) and then by medical conditions and drug exposures (14,595/132,664, 11%). A higher proportion of people living with HIV experienced COVID-19–related hospitalization (4650,132,664, 3.5%) or mortality (828/132,664, 0.6%) and all-cause mortality (2083/132,664, 1.6%) compared to other cohorts. CONCLUSIONS Using an extensive phenotyping algorithm leveraging granular data in an EHR repository, we have identified people living with HIV, people not living with HIV, PrEP users, and PEP users. Our findings offer transferable lessons to optimize future EHR phenotyping for these cohorts.

Year:

2024

The association between HIV-1 seroconversion and gut dysbiosis is well documented, and its association with sexual activity is also widely recognized. However, it is not known whether the gut dysbiosis mediates the effects of high-risk sexual behavior on HIV-1 seroconversion. In this report we focused on men who engaged in high-risk sexual behavior where they had receptive anal intercourse with multiple men. We demonstrate that proinflammatory cytokines, sCD14 and sCD163, and gut microbiota mediate the effects of this high-risk sexual behavior on subsequent HIV seroconversion. We discovered changes in the gut microbial ecology, prior to seroconversion, both in terms of the composition as well as inter-relationships among the commensal species. Furthermore, these changes correlate with future HIV seroconversion. Specifically, as the number of sexual partners increased, we discovered in a “dose-response” manner, a decrease in the abundance of commensal and short-chain fatty acid-producing species, A. muciniphila, B. caccae, B. fragilis, B. uniformis, Bacteroides spp., Butyricimonas spp. , and Odoribacter spp , and an increase in proinflammatory species Dehalobacterium spp. and Methanobrevibacter spp. These changes were also observed among subsequent HIV seroconverters. Interestingly, we also discovered a reduction in correlations among these commensal and short-chain fatty acid producing bacteria in a “dose-response” manner with the number of sexual partners. Our mediation analysis not only provides a conceptual model for the disease process but also provides clues for future clinical interventions that will manipulate the gut microbiota to treat high-risk subjects to prevent HIV seroconversion.

Year:

2024

Collaborators (18)

Alfred Anzalone

University of Nebraska Medical Center

UNITED STATES
View details

Jillian Phallen

Johns Hopkins University School of Medicine

UNITED STATES
View details

Lesley Jackson

Assistant Professor

The University of Alabama

UNITED STATES
View details

Todd T Brown

Professor

Johns Hopkins University

UNITED STATES
View details

Dongmei Li

Professor

University of Rochester

UNITED STATES
View details

Jessica Islam

Assistant Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Julie McMurry

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Dimitrios Mathios

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Victor E. Velculescu

Assistant/Associate/Professor of Oncology and Pathology

Johns Hopkins University School of Medicine

UNITED STATES
View details

Cara D. Varley

Oregon Health & Science University

UNITED STATES
View details

Sandra Safo

Faculty, Associate Professor

University of Minnesota

UNITED STATES
View details

Melissa Haendel

Director of Precision Health & Translational Informatics

University of North Carolina at Chapel Hill

UNITED STATES
View details

Kara Chew

Associate Professor

University of California, Los Angeles

UNITED STATES
View details

Huang Lin

Assistant Professor

University of Maryland

UNITED STATES
View details

Zachary Dozier

Assistant Professor

Stanford University

UNITED STATES
View details

Rena Patel

The University of Alabama

UNITED STATES
View details

Nada Fadul

Professor

University of Nebraska Medical Center

UNITED STATES
View details

Robert B Scharpf

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details